Prostate Cancer Diagnoses Set To Double As New Zealand Faces Treatment Crisis

Health advocates warn of looming healthcare burden without immediate government intervention

New Zealand's healthcare system faces a mounting crisis as prostate cancer diagnoses are projected to double over the next 20 years, while the country continues to lag behind international best practice in both prevention and treatment.

With over 700 New Zealand men dying from prostate cancer annually, advocates are highlighting a stark disparity: while breast, cervical, and bowel cancers have established screening programmes, prostate cancer remains without systematic early detection measures.

"This disease will likely impact almost every New Zealand family, yet we're treating it as an afterthought," said Jim Duthie, Consultant Urologist. "Our response needs to match the scale of the challenge."

The Men's Health Challenge

“Kiwi men over 50 need to fundamentally change their relationship with healthcare, starting with understanding basic anatomy and why the prostate is worthy of attention, and embracing regular health monitoring.

"Not having visited a GP in 20 years is not a badge of honour," continues Mr Duthie. "A yearly health check should be as routine as getting your car's WOF – as much for your own sake as for those who love you.

“Prostate cancer is a family issue. Not only does a diagnosis impact the whole whānau, but the risk of developing it increases by up to 11 times if a first or second degree relative has also had prostate cancer or breast cancer. If your GP isn’t offering you a regular PSA test, you need to start asking as soon as you hit the 50 milestone, and even earlier if you have a family history of the disease.”

Peter Dickens, CEO of the Prostate Cancer Foundation NZ, agrees that that men need community support to overcome traditional reluctance to seek medical help, particularly for a disease that, when detected early, is highly treatable.

Healthcare Infrastructure Gap

Speaking at a Blue September Parliamentary event this evening, Mr Duthie outlined that beyond early detection, New Zealand's public health system lacks modern treatment options readily available in comparable countries. Current gaps include robotic surgery capabilities, stereotactic radiotherapy, latest generation medicines, and properly resourced active surveillance programmes.

"We're asking patients to accept second-tier treatment options while watching their disease progress," explained Mr Duthie. "This creates an avoidable pathway to metastatic and incurable disease."

Economic and Social Impact

The projected surge in cases threatens to overwhelm an already stretched healthcare system, creating longer wait times and forcing difficult treatment rationing decisions.

"The question isn't whether we can afford to act – it's whether we can afford not to," Mr Duthie emphasised. "Prevention and early intervention are far more cost-effective than managing advanced disease. This is a challenge we are seeing our international peers - the UK and Australia specifically -

begin to tackle and our New Zealand men deserve the same attention and support"

Government Action Required

Prostate Cancer advocates are calling for a comprehensive national response including centralised risk-stratified early detection, upgraded public health facilities, and equitable access to international-standard treatments. The Prostate Cancer Foundation New Zealand has been advocating for a two district, four-year pilot screening programme with the objective of detecting medium and high-risk prostate cancers early, when effective medical interventions can do the most good.

The programme would cost approximately $6.5 million funding over four years but could potentially return over $100 million to the health system in cost savings, generate over half a billion in health gains, and avoid nearly $1 million in personal income loss for working-age men.

"Our leaders understand the importance of screening for other cancers – prostate cancer deserves the same priority and investment," Mr Duthie concluded.

NZ First Member’s Bill to Pilot Early Detection Prostate Cancer Screening

The Prostate Cancer Foundation NZ CEO Peter Dickens said the Foundation welcomes the news that NZ First has announced a Member’s Bill to establish a four-year pilot prostate cancer screening programme in two regions – one in the North Island and one in the South Island.

"This is an issue of national importance, and we are delighted that people are listening and grateful for NZ First’s support. We have secured an open invitation from the EU-sponsored world-leading PRAISE-U consortium for New Zealand to join its European Union screening pilots that involve 25 institutions across 12 countries, aimed at reducing prostate cancer deaths through smart early detection. This bill will allow NZ to join this initiative and learn the vital lessons specific to our unique population of at-risk men that can only be learned from pilots in New Zealand, while simultaneously benefiting from and contributing to the knowledge and understanding gathered at the wider global community of sites.

“We'd ask all members of Parliament to get behind this bill, across party lines. We owe it to every man in New Zealand to take this issue seriously. If we can demonstrate this is truly an issue of national importance, then we can start having more open conversations about this devastating disease and the steps needed to address it."

Notes: 

• Prostate cancer is the most commonly diagnosed cancer in New Zealand with around 4,000 diagnosed every year [exceeding breast cancer levels], at an average of 10 every day.
• Prostate cancer is the second highest cause of cancer death in men after lung cancer, and the third highest for all sexes (behind lung and bowel cancers).
• More than 700 men die on average every year from prostate cancer.
• Early detection significantly improves treatment outcomes.
• 61% of prostate cancer survivors say they had no symptoms when diagnosed.
• A PSA blood test is all it takes to start the process – simple and quick.
• Anyone can get prostate cancer, including transgender women, male-assigned non-binary or intersex people.
• For more information on PRAISE-U visit Praise-U

© Scoop Media